Literature DB >> 23123109

[The irido-corneo-endothelial syndrome. The loss of the control of corneal endothelial cell cycle. A review].

A M Robert1, G Renard, L Robert, J-L Bourges.   

Abstract

The three major symptoms of the irido-corneo-endothelial syndrome are the alterations of the corneal endothelium and of the iris with a loss of the regulation of the cell cycle, and the progressive obstruction of the irido-corneal angle. This rare pathology attacks mainly young adult women. Most of the symptoms and complications originate from the excessive proliferation of the corneal endothelial cells accompanied by the evolution of their phenotype towards that of the epithelial cells. In normal conditions the corneal endothelial cells do not divide, they are blocked in the G1 stage of the cell cycle, mainly because of the action of the inhibitors of cyclin-dependent kinases. Still these cells retain a good capacity for proliferation, which can be induced by the down-regulation of the expression of the inhibitors of the cyclin-dependent kinases. This proliferative capacity declines with age and is also different according to the localization of the cells: it is more intense with those originating from the central area then in those from the peripheral area of the cornea. The age-related decline of the proliferative capacity is not due to the shortening of the telomers, but to the stress-induced accelerated senescence of the cells.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23123109     DOI: 10.1016/j.patbio.2012.09.002

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

Review 1.  Diseases of the corneal endothelium.

Authors:  Lauren J Jeang; Curtis E Margo; Edgar M Espana
Journal:  Exp Eye Res       Date:  2021-02-14       Impact factor: 3.467

2.  Macular edema in Cogan-Reese syndrome.

Authors:  Hugo Bouvarel; Pascale Hamard; Emilie Agard; Jérémy Billant; Hussam El Chehab; Corinne Dot
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.